Advanced Search
Newsfeed
Followed Companies
News Alerts
118Followers on Owler
OverviewCompetitorsFundingInvestmentsNews & Insights

Seres Therapeutics Competitors' Key Highlights

Key Highlights

Sign up for free to see more
Sign up for free to see more
Sign up for free to see more
Funding
More (3+)
Evelo Biosciences received $79.2M in Post-IPO Equity Funding
Jun 02, 2022
Vedanta received $68M in Series D Funding
Jul 21, 2021
Product Launch
Qiagen N : gives drug research direct access to world-leading data with launch of Biomedical Knowledge Base
Apr 25, 2022
Partnership
More (3+)
Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration
Mar 02, 2022
Kaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD Foundation
Jan 31, 2022
Conference Presentation
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
ESG
Qiagen N : Global Environmental Health Safety Policy
Mar 31, 2022
Fraud
Kaleido Biosciences Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Kaleido Biosciences, Inc.
Apr 11, 2022
Acquisition
Indigo acquired Soil Metrics for undisclosed amount
Oct 27, 2021
QIAGEN acquired BLIRT S.A. for undisclosed amount
May 11, 2022
Layoffs
Finch cuts one-fifth of staff amid Hep B program pause
Apr 19, 2022
Kaleido Biosciences is winding up operations as bluebird bio and other biotech firms announce layoffs
Apr 11, 2022

Seres Therapeutics Competitors or Alternatives

Seres Therapeutics's top competitors include Evelo Biosciences, Second Genome and Vedanta.

Sign up for free to unlock more info

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

  • CEO

    CEO RATING

    EMPLOYEES

  • FUNDING

    REVENUE

  • CEO

    CEO RATING

  • EMPLOYEES

    FUNDING

  • REVENUE

  • CEO

  • CEO RATING

  • EMPLOYEES

  • FUNDING

  • REVENUE

Seres Therapeutics's company profile

Eric D. Shaff

President & CEO

87/100
330
$267.9M
$140.7M

  • Eric D. Shaff

    President & CEO

    87/100
    330
  • $267.9M
    $140.7M

  • Eric D. Shaff

    President & CEO

    87/100
  • 330
    $267.9M
  • $140.7M

  • Eric D. Shaff

    President & CEO

  • 87/100
  • 330
  • $267.9M
  • $140.7M
View ProfileView
1
Seres Therapeutics's Competitor - Evelo Biosciences logo

Simba Gill

President & CEO

89/100
120
$290.7M
$1.5M

  • Simba Gill

    President & CEO

    89/100
    120
  • $290.7M
    $1.5M

  • Simba Gill

    President & CEO

    89/100
  • 120
    $290.7M
  • $1.5M

  • Simba Gill

    President & CEO

  • 89/100
  • 120
  • $290.7M
  • $1.5M
View ProfileView
2
Seres Therapeutics's Competitor - Second Genome logo

Karim Dabbagh

President & CEO

83/100
60
$68.7M
$12M

  • Karim Dabbagh

    President & CEO

    83/100
    60
  • $68.7M
    $12M

  • Karim Dabbagh

    President & CEO

    83/100
  • 60
    $68.7M
  • $12M

  • Karim Dabbagh

    President & CEO

  • 83/100
  • 60
  • $68.7M
  • $12M
View ProfileView
3
Seres Therapeutics's Competitor - Vedanta logo

Bernat Olle

Co-Founder & CEO

84/100
90
$308.6M
$8M

  • Bernat Olle

    Co-Founder & CEO

    84/100
    90
  • $308.6M
    $8M

  • Bernat Olle

    Co-Founder & CEO

    84/100
  • 90
    $308.6M
  • $8M

  • Bernat Olle

    Co-Founder & CEO

  • 84/100
  • 90
  • $308.6M
  • $8M
View ProfileView
4
Seres Therapeutics's Competitor - Synlogic logo

Aoife M. Brennan

President & CEO

85/100
80
$256.9M
$2M

  • Aoife M. Brennan

    President & CEO

    85/100
    80
  • $256.9M
    $2M

  • Aoife M. Brennan

    President & CEO

    85/100
  • 80
    $256.9M
  • $2M

  • Aoife M. Brennan

    President & CEO

  • 85/100
  • 80
  • $256.9M
  • $2M
View ProfileView
5
Seres Therapeutics's Competitor - Finch logo

Mark Smith

CEO

86/100
190
$312.9M
$15.3M

  • Mark Smith

    CEO

    86/100
    190
  • $312.9M
    $15.3M

  • Mark Smith

    CEO

    86/100
  • 190
    $312.9M
  • $15.3M

  • Mark Smith

    CEO

  • 86/100
  • 190
  • $312.9M
  • $15.3M
View ProfileView
6
Seres Therapeutics's Competitor - Indigo logo

Ronald Hovsepian

President & CEO

84/100
1,000
$1.2B
$1B

  • Ronald Hovsepian

    President & CEO

    84/100
    1,000
  • $1.2B
    $1B

  • Ronald Hovsepian

    President & CEO

    84/100
  • 1,000
    $1.2B
  • $1B

  • Ronald Hovsepian

    President & CEO

  • 84/100
  • 1,000
  • $1.2B
  • $1B
View ProfileView
7
Seres Therapeutics's Competitor - Kaleido logo

Daniel Menichella

President & CEO

90/100
80
$226.4M
$1.1M

  • Daniel Menichella

    President & CEO

    90/100
    80
  • $226.4M
    $1.1M

  • Daniel Menichella

    President & CEO

    90/100
  • 80
    $226.4M
  • $1.1M

  • Daniel Menichella

    President & CEO

  • 90/100
  • 80
  • $226.4M
  • $1.1M
View ProfileView
8
Seres Therapeutics's Competitor - Axial logo

Stewart A. Campbell

CEO

84/100
60
$94.5M
$5.2M

  • Stewart A. Campbell

    CEO

    84/100
    60
  • $94.5M
    $5.2M

  • Stewart A. Campbell

    CEO

    84/100
  • 60
    $94.5M
  • $5.2M

  • Stewart A. Campbell

    CEO

  • 84/100
  • 60
  • $94.5M
  • $5.2M
View ProfileView
9
Seres Therapeutics's Competitor - Symbiotix Biotherapies logo

Nader Yaghoubi

President & CEO

70/100
$5M

  • Nader Yaghoubi

    President & CEO

    70/100
  • $5M

  • Nader Yaghoubi

    President & CEO

    70/100
  • $5M

  • Nader Yaghoubi

    President & CEO

  • 70/100
  • $5M
View ProfileView
10
Seres Therapeutics's Competitor - Xeno Biosciences logo

Hasan Celiker

Founder & CEO

70/100
$1.2M

  • Hasan Celiker

    Founder & CEO

    70/100
  • $1.2M

  • Hasan Celiker

    Founder & CEO

    70/100
  • $1.2M

  • Hasan Celiker

    Founder & CEO

  • 70/100
  • $1.2M
View ProfileView
11
Seres Therapeutics's Competitor - Menarini Silicon Biosystems. logo

Giuseppe Giorgini

Chairman & CEO

66/100
119
$6.8M
$2.1M

  • Giuseppe Giorgini

    Chairman & CEO

    66/100
    119
  • $6.8M
    $2.1M

  • Giuseppe Giorgini

    Chairman & CEO

    66/100
  • 119
    $6.8M
  • $2.1M

  • Giuseppe Giorgini

    Chairman & CEO

  • 66/100
  • 119
  • $6.8M
  • $2.1M
View ProfileView
12
Seres Therapeutics's Competitor - Pharmetheus logo

CEO

- -
- -

  • CEO

    - -
  • - -

  • CEO

    - -
  • - -

  • CEO

  • - -
  • - -
View ProfileView
The top 10 competitors in Seres Therapeutics' competitive set are Evelo Biosciences, Second Genome, Vedanta, Synlogic, Finch, Indigo, Kaleido, Axial, Symbiotix Biotherapies, Xeno Biosciences. and DayTwo. Together they have raised over 3.4B between their estimated 8.2K employees. Seres Therapeutics has 330 employees and is ranked 3rd among it's top 10 competitors. The top 10 competitors average 570.

Evelo Biosciences is one of Seres Therapeutics's top competitors. Evelo Biosciences is a Public company that was founded in Cambridge, Massachusetts in 2014. Evelo Biosciences is in the Biotechnology field. Evelo Biosciences has 208 fewer employees vs. Seres Therapeutics.

Second Genome is perceived as one of Seres Therapeutics's biggest rivals. Second Genome was founded in 2009 in Brisbane, California. Second Genome competes in the Biotechnology industry. Second Genome generates $128.7M less revenue than Seres Therapeutics.

Vedanta is a top competitor of Seres Therapeutics. Vedanta's headquarters is in Cambridge, Massachusetts, and was founded in 2010. Vedanta competes in the Biotechnology field. Vedanta generates 5.69% of Seres Therapeutics's revenue.

Looking for similar companies to Seres Therapeutics?

Trending News for Seres Therapeutics and Seres Therapeutics's Competitors

June 30, 2022Markets Insider
(RTTNews) - Seres Therapeutics, Inc. (MCRB), a microbiome therapeutics firm, on Thursday announced the registered direct offering of 31.746 millio......
June 30, 2022MarketScreener
(marketscreener.com) Detailed Tax Disclosure according GRI 207-4/Country-by-country reporting Country-by-country reporting requires multinational enter...
June 30, 2022Citybizlist
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entere...

Frequently Asked Questions about Seres Therapeutics

  1. Who are Seres Therapeutics's top competitors?

    Seres Therapeutics's top 3 competitors are Evelo Biosciences, Second Genome, Vedanta.

  2. Who is similar to Seres Therapeutics?

    Evelo Biosciences is the most similar to Seres Therapeutics. Second Genome and Vedanta are also similar to Seres Therapeutics.

  1. Are Seres Therapeutics and Evelo Biosciences competitors?

    Yes, Evelo Biosciences is one of Seres Therapeutics’s top competitors.